ArticleHaematologica2021
Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial.
Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.British journal of haematology · 2026Trial
- Self-reported geriatric impairments and treatment toxicity in older patients with multiple myeloma.Blood advances · 2026Observational
- Advances in the application of frailty scoring in the diagnosis and management of elderly patients with multiple myeloma (Review).Oncology reports · 2026Review
- Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple Myeloma.Research square · 2026Article
- Cumulative deficits frailty index and relationship status predict survival in multiple myeloma.Blood advances · 2025Article
- Optimizing individualized therapy decision-making in multiple myeloma (MM): integration and impact of the Revised Myeloma Comorbidity Index in the MM-tumor board.Annals of hematology · 2025Article
- Personalized Treatment of Multiple Myeloma in Frail Patients.Current oncology reports · 2024Review
- An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence.Haematologica · 2023Article
- Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers.Annals of hematology · 2023Article
- The limited use of autologous hematopoietic stem cell transplant for fit older patients with multiple myeloma in India: a retrospective analysis.Journal of the Egyptian National Cancer Institute · 2022Article
- Review
- Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents.Bone marrow transplantation · 2021Article
- Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures.BMC cancer · 2021Article
- Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany.Haematologica · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.